Finished

Post-traumatic stress disorder (PTSD)

Post-traumatski stresni poremećaj (PTSP)

Drug: The drug under study acts on TRPC4 ion channels and represents a completely new potential option for the treatment of a number of mental disorders and migraine headaches.

Method of administration: The drug is taken in tablet form.
Duration and design of the study: Patients will receive a study drug or placebo for 2 months.

Why participate in the survey?

Therapeutic options in patients with PTSD are limited to the use of antidepressants from the group of SSRI inhibitors and anxiolytics, so there is a great need to discover a new drug. Great contribution to the clinical experience with a completely new group of drugs in psychiatry. The effectiveness of the treatment will be monitored by a team of three top psychiatric specialists.

Persons who are potential candidates for participation:

  1. Men and women aged 18-65 years.
  2. Diagnosed with PTSD at any time in the past.
  3. Moderate or severe disease (> 33 points according to the PCL-5 questionnaire).
  4. Patients can take all other types of PTSD medication if the dose is stable over the last 2 months.

Persons NOT candidates for participation in the survey:

  1. Parallel diagnosis of schizophrenia, psychotic episodes or bipolar disorder.
  2. Addiction to alcohol or other psychoactive substances.

Start of patient involvement: May 2022.
Completion of inclusion of patients in the study: Until the quota is filled

Tell us more about yourself and your illness: →

Would you like to know more information on:

Post-traumatic stress disorder (PTSD)

Contact us

Testimonials from
our patients

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations